Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin

Liver International

Volumn 28, Issue 3, 2008, Pages 407-411

  Vukotic, Ranka ^a   Gramenzi, Annagiulia ^a   Vitale, Giovanni ^a   Cursaro, Carmela ^a   Serra, Carla ^a   Biselli, Maurizio ^a   Scuteri, Alessandra ^a   Andreone, Pietro ^a,b   Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiviral therapy; HepatitisC virus; Hepatocellular carcinoma; Long termfollow up

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2B INTERFERON; AMINOTRANSFERASE; RIBAVIRIN; SONOVUE; VIRUS RNA;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE SURVEILLANCE; DRUG RESPONSE; ECHOGRAPHY; FATTY LIVER; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION;

EID: 39649115614     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01593.x     Document Type: Article

References (34)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(Suppl. 1): S35-46.
4. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 6547-9.
5. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
6. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 1995; 21: 650-5.
7. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127(Suppl. 1): S35-50.
8. CammàC, Giunta M, Andreone P, CraxìA. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001; 34: 593-602.
9. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
10. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
11. Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 2004; 10(Suppl. 1): S115-20.
12. Bosch FX, Ribes J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(Suppl. 1): S5-16.
13. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-5.
14. Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: Effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-44.
15. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996; 226: 176-82.
16. Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: Lessons from animal model studies. Clin Gastroenterol Hepatol 2005; 3(Suppl. 2): S132-5.
17. Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164-72.
18. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
19. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A meta-analysis. Aliment Pharmacol Ther 2001; 15: 689-98.
20. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated to improved outcome in HCV related cirrhosis: A retrospective study. Hepatology 2007; 45: 579-87.
21. Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained virological response to interferon therapy: A multicenter, retrospective cohort study of 1124 patients. Liver Int 2007; 27: 186-91.
22. Kubo S, Nishiguchi S, Tamori A, et al. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C. Hepatogastroenterology 2000; 47: 1100-2.
23. Hirashima N, Mizokami M, Orito E, et al. Case report: Development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon α. J Gastroenterol Hepatol 1996; 11: 955-8.
24. Yamaguchi K, Omagari K, Kinoshita H, et al. Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-alpha. J Clin Gastroenterol 1999; 29: 207-9.
25. Miyano S, Togashi H, Shinzawa H, et al. Case report: Occurrence of hepatocellular carcinoma 4.5 years after successful treatment with virus clearance for chronic hepatitis C. J Gastroenterol Hepatol 1999; 14: 928-30.
26. Inoue M, Ohhira M, Ohtake T, et al. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy. Hepatogastroenterology 1999; 46: 2554-60.
27. Yamaura T, Matsumoto A, Rokuhara A, et al. Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy. J Gastroenterol Hepatol 2002; 17: 1229-35.
28. Yamada M, Ichikawa M, Matsubara A, Ishiguro Y, Yamada M, Yokoi S. Development of small hepatocellular carcinoma 80 months after clearance of hepatitis C virus with interferon therapy. Eur J Gastroenterol Hepatol 2000; 12: 1029-32.
29. Sugiura N, Sakai Y, Ebara M, et al. Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: Clinical study of 26 cases. J Gastroenterol Hepatol 1996; 11: 535-9.
30. Tomimatsu M, Endo H, Kitazawa M, et al. Type C chronic hepatitis with the discovery of a small hepatocellular carcinoma 7 years after successful interferon therapy. J Gastroenterol 2003; 38: 395-8.
31. Ito Y, Yamamoto N, Nakata R, et al. Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol 2005; 11: 7218-21.
32. Sieja KS, Everson GT. De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to Interferon/ribavirin therapy. Dig Dis Sci 2006; 51: 600-2.
33. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-402.
34. Lerat H, Honda M, Beard M, et al. Steatosis and liver cancer in transgenic mice expressing the structural and non structural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-65.